MedTrace Logo

Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse

NCT00180947 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2006-09-08

No results posted yet for this study

Summary

This is a phase II study to determine the antitumor activity of Vinorelbine and Cyclofosfamide association among patients with refractory tumours or in relapse with rhabdomyosarcomas and other soft tissue tumours, Ewing tumours, osteosarcomas, neuroblastomas or medulloblastomas.

Conditions

  • Rhabdomyosarcomas
  • Neoplasms, Connective and Soft Tissue
  • Ewing Tumor
  • Osteosarcomas
  • Neuroblastomas
  • Medulloblastomas

Interventions

DRUG

Vinorelbine, cyclofosfamide

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Odile OBERLIN, MD · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180947 on ClinicalTrials.gov